Increase in GLUT1 in smooth muscle alters vascular contractility and increases inflammation in response to vascular injury

Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):86-94. doi: 10.1161/ATVBAHA.110.215004. Epub 2010 Oct 14.

Abstract

Objective: The goal of this study was to test the contributing role of increasing glucose uptake in vascular smooth muscle cells (VSMCs) in vascular complications and disease.

Methods and results: A murine genetic model was established in which glucose trasporter 1 (GLUT1), the non-insulin-dependent glucose transporter protein, was overexpressed in smooth muscle using the sm22α promoter. Overexpression of GLUT1 in smooth muscle led to significant increases in glucose uptake (n=3, P<0.0001) as measured using radiolabeled 2-deoxyglucose. Fasting blood glucose, insulin, and nonesterified fatty acids were unchanged. Contractility in aortic ring segments was decreased in sm22α-GLUT1 mice (n=10, P<0.04). In response to vascular injury, sm22α-GLUT1 mice exhibited a proinflammatory phenotype, including a significant increase in the percentage of neutrophils in the lesion (n=4, P<0.04) and an increase in monocyte chemoattractant protein-1 (MCP-1) immunofluorescence. Circulating haptoglobin and glutathione/total glutathione were significantly higher in the sm22α-GLUT1 mice postinjury compared with controls (n=4, P<0.05), suggesting increased flux through the pentose phosphate pathway. sm22α-GLUT1 mice exhibited significant medial hypertrophy following injury that was associated with a significant increase in the percentage of VSMCs in the media staining positive for nuclear phosphoSMAD2/3 (n=4, P<0.003).

Conclusions: In summary, these findings suggest that increased glucose uptake in VSMCs impairs vascular contractility and accelerates a proinflammatory, neutrophil-rich lesion in response to injury, as well as medial hypertrophy, which is associated with enhanced transforming growth factor-β activity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / metabolism
  • Aorta / physiopathology
  • Blood Glucose / metabolism
  • Cells, Cultured
  • Chemokine CCL2 / metabolism
  • Deoxyglucose / metabolism
  • Disease Models, Animal
  • Fatty Acids, Nonesterified / blood
  • Femoral Artery / injuries
  • Femoral Artery / metabolism
  • Glucose Transporter Type 1 / genetics
  • Glucose Transporter Type 1 / metabolism*
  • Glutathione / blood
  • Haptoglobins / metabolism
  • Humans
  • Hypertrophy
  • Inflammation / etiology*
  • Inflammation / metabolism
  • Inflammation / pathology
  • Insulin / blood
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Microfilament Proteins / genetics
  • Muscle Proteins / genetics
  • Muscle, Smooth, Vascular / injuries
  • Muscle, Smooth, Vascular / metabolism*
  • Muscle, Smooth, Vascular / pathology
  • Muscle, Smooth, Vascular / physiopathology
  • Myocytes, Smooth Muscle / metabolism*
  • Myocytes, Smooth Muscle / pathology
  • Neutrophil Infiltration
  • Phosphorylation
  • Promoter Regions, Genetic
  • Smad2 Protein / metabolism
  • Smad3 Protein / metabolism
  • Up-Regulation
  • Vasoconstriction*

Substances

  • Blood Glucose
  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Fatty Acids, Nonesterified
  • Glucose Transporter Type 1
  • Haptoglobins
  • Insulin
  • Microfilament Proteins
  • Muscle Proteins
  • SLC2A1 protein, human
  • Smad2 Protein
  • Smad2 protein, mouse
  • Smad3 Protein
  • Smad3 protein, mouse
  • transgelin
  • Deoxyglucose
  • Glutathione